welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients With Duchenne Muscular Dystrophy Treated With Lead Candidate CAP-1002


Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. Boys and young men typically lose their ability to walk in their teens and generally die of cardiac or respiratory complications by the 3rd decade of life. The data showed improvements in upper limb, cardiac and respiratory function with p-values less than p=0.05 in multiple measures.

The 12-month data from HOPE-2 showed statistically meaningful improvements in the PUL 2.0 in CAP-1002 treated patients (p=0.05) with a mean change of 2.4 points over placebo patients. With the exception of steroids, preservation of function in DMD is uncommon.

 

Capricor Announces Positive Top-Line Final Results From HOPE-2 Study In Patients With Duchenne Muscular Dystrophy Treated With Lead Candidate CAP-1002